La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

T. Di Paolo27
Traitement285
T. Di Paolo Sauf Traitement" 17
Traitement Sauf T. Di Paolo" 275
T. Di Paolo Et Traitement 10
T. Di Paolo Ou Traitement 302
Corpus1799
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 10.
Ident.Authors (with country if any)Title
000937 A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada]New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable
000B60 M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
000B96 M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS
000E58 F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada]Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex
000F44 B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. BedardEffect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors
000F50 C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada]Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors
001063 C. Rouillard ; P. J. Bedard ; T. Di PaoloEffects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393
001064 C. Gagnon ; P. J. Bedard ; T. Di PaoloEffect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists
001126 P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di PaoloBehavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys
001184 P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. BoucherChronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022